Tesamorelin

Plain-language summary

A growth-hormone-releasing factor analog and the only FDA-approved medication to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.

Regulatory status

Evidence snapshot

Established. Supported by multiple well-conducted randomized trials and/or systematic reviews with consistent results.

How it works

Acts as a growth-hormone-releasing hormone analog, stimulating the pituitary to release growth hormone, which reduces visceral fat.

Approved uses and researched uses

Researched uses are studied but not FDA-approved and may be off-label. This is not a recommendation to use them.

Known risks and uncertainties

Effects can include joint pain, swelling, injection-site reactions, and increased blood sugar/glucose intolerance. Because it raises growth hormone/IGF-1, it is generally avoided in active malignancy and requires monitoring. It is not indicated for general weight loss.

Cautions and contraindications

Contraindicated in active malignancy, in pregnancy, and in patients with disruption of the hypothalamic-pituitary axis (e.g., from tumor, surgery, radiation, or trauma); caution with diabetes given effects on glucose.

Consumer considerations

• FDA approval is specifically for HIV-associated lipodystrophy, not general fat loss.
• It raises growth hormone and IGF-1, so cancer screening and glucose monitoring matter.
• It requires daily or weekly injection depending on formulation.
• Benefits typically reverse after stopping treatment.
• Off-label use for aesthetics is not supported by its approval.

Questions to ask a licensed clinician

• Is this appropriate for my specific condition versus off-label use?
• How will my blood sugar and IGF-1 be monitored?
• What cancer-screening precautions apply before and during treatment?
• How long is treatment expected to last and what happens if I stop?
• What side effects should prompt me to call you?

Sources